1. OctreoTher[sup TM] : Ongoing Early Clinical Development of a Somatostatin-Receptor-Targeted Radionuclide Antineoplastic Therapy.
- Author
-
Smith, M. Charles, Jingou Liu, M. Charles, Tianling Chen, M. Charles, Schran, Horst, Ching-Ming Yeh, Jamar, François, Valkema, Roelf, Bakker, Willem, Kvols, Larry, Krenning, Eric, and Pauwels, Stanislas
- Subjects
- *
BREAST cancer , *NEUROENDOCRINE tumors , *RADIOISOTOPE therapy , *SMALL cell lung cancer , *SOMATOSTATIN , *YTTRIUM - Abstract
OctreoTher[sup TM] ([sup 90] Y-DOTA-D-Phe[sup 1] -Tyr[sup 3] -octreotide, a.k.a. [sup 90] Y-SMT 487) consists of a somatostatin peptide analogue (Tyr[sup 3] -octreotide), coupled with a complexing moiety (DOTA), and labeled with a tightly bound beta-emitter (yttrium-90). By targeting somatostatin receptor-positive tumors (as imaged by OctreaScan[sup ®] ) it may deliver a tumoricidal dose of radiation. Phase I clinical trials, conducted in patients with neuroendocrine tumors, established the safety and tolerability of the dose selected for further study and demonstrated the capacity of OctreoTher to deliver radiation doses to tumors that resulted in significant neuroendocrine tumor shrinkage. Novartis-sponsored phase II studies will soon begin to test the efficacy of OctreoTher in breast and small cell lung cancer. A fixed-dose regimen of 120 mCi/cycle × 3 cycles administered with concomitant amino acid infusion has been chosen for the study. Phase I data and published literature support that this fixed dose regimen will be safely tolerated.Copyright © 2000 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF